{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications. (PHOEBUS)","eudractNumber":"2022-501831-18","id":11222,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2025-11-27T13:57:47+01:00","shortTitle":"PHOEBUS - MPOH08","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling","eudractNumber":"2024-512360-55-00","id":12010,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-low","id":"mt_286"}],"nctNumber":"NCT06486883","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":null,"shortTitle":"PONTIAC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Prospektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualit&#228;t in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheits&#246;konomie PRAEGNANT Brustkrebs: Fortgeschritten/ Metastasierend<div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><br /></div>","eudractNumber":"2014-000854-12","id":4161,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02338167","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-08-26T14:23:16+02:00","shortTitle":"PRAEGNANT Mammakarzinom","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"PRESS -PAR: Early detection and PREvention of Symptomatic\npostSurgical hypoPARathyroidism\nafter thyroid surgery","eudractNumber":null,"id":9865,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-15T09:25:46+02:00","shortTitle":"PRESSPAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs w&#228;hrend einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antik&#246;rper Therapie","eudractNumber":null,"id":8562,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05425550","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-06-01T14:29:03+02:00","shortTitle":"PRO2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>PROstate CAncer Real World Evidence Registry: Registerstudie zur Erfassung des Therapie- und Krankheitsverlaufs bei Patienten mit rezidiviertem und metastasiertem Prostatakrebs</div><div><br /></div><div>DRKS00033411</div>","eudractNumber":null,"id":10394,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-07T09:20:45+01:00","shortTitle":"PROCARE","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Real world experience of patients with metastatic castration resistant prostate Cancer treated with Olaparib+Abiraterone","eudractNumber":null,"id":9252,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:32:33+01:00","shortTitle":"PROCEED","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:justify;\">PRODIGE\n107- ENGIC 01- COLOSOTO</p>\n\n<p class=\"MsoNormal\" align=\"center\" style=\"text-align:justify;\">A single-arm phase II\nstudy evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib\n(KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a\ndoublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated\ncolorectal adenocarcinoma</p>","eudractNumber":"2024-514030-20-00","id":11576,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-02-04T11:57:45+01:00","shortTitle":"PRODIGE 107-COLOSOTO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Pre-Operative Treatment in rEseCTable cOlon canceR</div><div>(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)</div><div>Prospective, randomized, open, multicenter Phase III trial</div><div>to investigate the efficacy preoperative systemic therapy in</div><div>advanced colon cancer</div>","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T09:29:32+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Erstellung eines immunhistochemischen PSMA Expressionsprofiles von Patienten mit neu diagnostizierten, metastasierten Tumoren&#160; des GI-Trakts. Anhand der Immunhistochemie Selektion von Patienten f&#252;r ein PSMA-PET/CT mit anschlie&#223;end visueller und semiquantitativer Bestimmung der PSMA Traceraktivit&#228;t in Prim&#228;rtumor und Metastasen.&#160;","eudractNumber":null,"id":8165,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05547919","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-10-01T12:04:46+02:00","shortTitle":"PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}